On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from ...

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago.

HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago.